Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children
Authors:
- 1 March 2009
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (3) , 521-526
Abstract
A randomized, open, coordinated multi-center trial compared the bacteriological and clinical efficacy and safety of orally administered ceftibuten and trimethoprim-sulfamethoxazole (TMP-SMX) in children with febrile urinary tract infection (UTI). Children aged 1 month to 12 years presenting with presumptive first-time febrile UTI were eligible for enrolment. A 2:1 assignment to treatment with ceftibuten 9 mg/kg once daily (n = 368) or TMP-SMX (3 mg + 15 mg)/kg twice daily (n = 179) for 10 days was performed. Escherichia coli was recovered in 96% of the cases. Among the E. coli isolates, 14% were resistant to TMP-SMX but none to ceftibuten. In the modified intention-to-treat population, the bacteriological elimination rates at follow-up did not differ significantly between patients treated with ceftibuten and those treated with TMP-SMX [91 vs. 95%, with a 95% confidence interval (CI) for difference of −9.7 to 1.0]. However, the clinical cure rate was significantly higher among those treated with ceftibuten (93 vs. 83%, with a 95% CI for difference of 2.4 to 17.0). Adverse events were similar for both regimens and consisted mainly of gastrointestinal disturbances. In conclusion, ceftibuten is a safe and effective drug for the empirical treatment of febrile UTI in young children.Keywords
This publication has 22 references indexed in Scilit:
- Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritisEuropean Journal of Pediatrics, 2007
- Antibiotics for acute pyelonephritis in children2007
- Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trialBMJ, 2007
- Prevalence and Predictors of Trimethoprim‐Sulfamethoxazole Resistance among UropathogenicEscherichia coliIsolates in MichiganClinical Infectious Diseases, 2002
- Fewer Bacterial Relapses after Oral Treatment with Norfloxacin than with Ceftibuten in Acute Pyelonephritis Initially Treated with Intravenous CefuroximeScandinavian Journal of Infectious Diseases, 2001
- Interpretation of the Bacteriologic Outcome of Antibiotic Treatment for Uncomplicated Cystitis: Impact of the Definition of Significant Bacteriuria in a Comparison of Ritipenem Acoxil with NorfloxacinClinical Infectious Diseases, 1995
- Initial clinical assessment of the comatose patientThe Pediatric Infectious Disease Journal, 1993
- Evaluation of New Anti-Infective Drugs for the Treatment of Urinary Tract InfectionClinical Infectious Diseases, 1992
- The pharmacokinetics of ceftibuten in humansDiagnostic Microbiology and Infectious Disease, 1991
- Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990